NRT is delighted to announce data from its Phase I First-in-Human Study of Yttrium-90 Carbon Microspheres (NRT6003) Injection, which demonstrated encouraging potential single-agent efficacy and a manageable safety profile in Chinese patients with unresectable hepatocellular carcinoma (HCC).

The data was presented in a poster presentation (Poster Bd #152, Abstract # 4169) at the American Society of Clinical Oncology (ASCO) Annual Meeting, held May 29 - June 2, 2026 in Chicago.

The study is a prospective, multicenter, open-label, single-arm trial (NCT06310590), designed to evaluate the safety and efficacy of NRT6003 Injection in the Chinese population with unresectable HCC. Primary endpoints include incidences of adverse events (AEs) and serious adverse events (SAEs), and localized objective response rate (ORR) in the initial treated area, assessed by mRECIST. A total of 40 patients with unresectable HCC from eight centers in China were enrolled.

Key Findings:

l  The best overall ORR and best localized ORR were 92.5% and 95.0%, respectively.

l  The confirmed overall ORR and localized ORR were 75.0% and 77.5%, respectively.

l  Six patients initially determined unresectable were successfully downstaged and subsequently underwent surgical resection.

l  Safety data also demonstrated favorable profile.

A pivotal multicenter, randomized controlled Phase III clinical trial (NCT06900543, CHEERS) of Yttrium-90 Carbon Microspheres Injection in unresectable HCC patients in China has completed enrollment of all participants. Meanwhile, clinical development for pancreatic cancer indication is progressing steadily.

About Yttrium-90 Carbon Microspheres Injection

Developed using NRT’s proprietary technology, the injection is administered via interventional procedures, allowing Yttrium-90 carbon microspheres to be delivered selectively into tumor-feeding blood vessels. High-energy beta emissions result in precise and effective internal irradiation, achieving targeted treatment of the tumor.

With an average tissue penetration depth of approximately 2.5 mm, Yttrium-90 has minimal impact on surrounding healthy tissue. The product utilizes a proprietary porous carbon carrier and a patented loading process for optimal suspension stability and specific activity.